Clinical and Molecular Characterization of AXL in Colorectal Cancer CALGB Alliance SWOG 80405 and Real-World Data


Karam Ashouri, Yan Yang, Joshua Millstein, Joanne Xiu, Shivani Soni, Sandra Algaze, Pooja Mittal, Alexandra Wong, Jae Ho Lo, Lesly Torres-Gonzalez, Priya Jayachandran, Wu Zhang, Anthony Shields, Richard Goldberg, Emil Lou, Benjamin Weinberg, John Marshall, Aaron Meyer, Francesca Battaglin, Heinz-Josef Lenz


  • AXL, a member of the TAM (TYRO3, AXL, and MER) family of receptor tyrosine kinases, plays a pivotal role in proliferation, survival, migration, and differentiation.
  • Dysregulation of AXL signaling is linked with chemotherapy and targeted therapy resistance.
  • A novel inhibitor of AXL Kinase, TP-0903, recently completed a phase 1 clinical trial for solid tumors including colorectal cancer [NCT02729298].
  • It remains unclear which patients may benefit from therapies targeting AXL, given its role in both tumor cell intrinsic resistance and immune microenvironmental reprogramming.
  • Here, we present a clinical and molecular characterization of AXL in colorectal cancer (CRC).
Download Publication